Samer Al Hadidi Institution-verified

Sourced from institutional research profiles (UAMS TRI or ARA).

Associate Professor , Clinical Director of Amyloidosis Program

UAMS

Last publication 2025 Last refreshed 2026-05-16

faculty

20 h-index 240 pubs 1,583 cited

Research Areas

Links

ORCID Lab Website UAMS TRI Profile

Edit your profile

OverviewAI-generated summary

Samer Al Hadidi, M.D., M.S., is an Associate Professor specializing in hematology and oncology, with a focus on plasma cell disorders and cellular therapies. His clinical work includes directing the Amyloidosis Program and leading the Fellows’ Plasma Cell Disorders Clinic. Dr. Al Hadidi earned his medical degree from the University of Jordan School of Medicine and completed his internal medicine residency at Hurley Medical Center/Michigan State University. He pursued fellowship training in hematology and oncology at Baylor College of Medicine and obtained a master’s degree in clinical research and statistical analysis from the University of Michigan.

Dr. Al Hadidi’s research investigates treatments for multiple myeloma and related conditions. He has published on the risk of infections associated with bispecific antibodies in multiple myeloma, the participation of Black Americans in cancer clinical trials, and disparities in access to CAR T-cell and bispecific antibody trials for multiple myeloma. His work also characterizes the immune microenvironment in multiple myeloma progression at a single-cell level and examines the changing spectrum of infections with BCMA and GPRC5D targeting bispecific antibody therapy. He has an h-index of 20 and has authored 240 publications, with 1,583 citations.

Metrics

h-index: 20
Publications: 240
Citations: 1,583

Selected Publications

Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)

DOI OpenAlex
Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026)

DOI OpenAlex
MM-1225: Comparison of Short-Term Outcomes and Safety Profile Between Daratumumab-Based Quadruplet Versus Triplet Induction Regimens for Patients With Transplant-Eligible Newly Diagnosed Multiple Myeloma: Meta-Analysis of Randomized Controlled Trials (2025)

DOI OpenAlex
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma (2025)

17 citations DOI OpenAlex
Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review (2025)

24 citations DOI OpenAlex
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024)

24 citations DOI OpenAlex
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma (2024)

8 citations DOI OpenAlex
Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab (2024)

7 citations DOI OpenAlex
Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma (2024)

9 citations DOI OpenAlex
Bispecific antibodies and autologous chimeric antigen receptor T cell therapies for treatment of hematological malignancies (2024)

18 citations DOI OpenAlex
Industry Payments to Physicians Endorsing Drugs and Devices on a Social Media Platform (2024)

6 citations DOI OpenAlex
Targeting GPRC5D in multiple myeloma (2024)

6 citations DOI OpenAlex
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study (2024)

85 citations DOI OpenAlex
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma (2024)

19 citations DOI OpenAlex
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems (2024)

7 citations DOI OpenAlex